Guardant Health
About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Employees: 2,021
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
93% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 46
38% more capital invested
Capital invested by funds: $3.65B [Q4 2024] → $5.05B (+$1.4B) [Q1 2025]
14% more funds holding
Funds holding: 296 [Q4 2024] → 337 (+41) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
0.7% less ownership
Funds ownership: 96.71% [Q4 2024] → 96.01% (-0.7%) [Q1 2025]
17% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 108
32% less call options, than puts
Call options by funds: $69.7M | Put options by funds: $102M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$57
32%
upside
Avg. target
$62
43%
upside
High target
$70
62%
upside
8 analyst ratings
8 positive
100%
0 neutral
0%
0 negative
0%
Mizuho Anthony Petrone | 50%upside $65 | Outperform Maintained | 13 Jun 2025 |
Piper Sandler David Westenberg | 39%upside $60 | Overweight Maintained | 6 May 2025 |
Scotiabank Sung Ji Nam | 32%upside $57 | Sector Outperform Maintained | 5 May 2025 |
Canaccord Genuity Kyle Mikson | 50%upside $65 | Buy Maintained | 1 May 2025 |
Stifel Daniel Arias | 39%upside $60 | Buy Maintained | 1 May 2025 |
Financial journalist opinion
Based on 3 articles about GH published over the past 30 days
Neutral
Business Wire
22 hours ago
New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the first clinical readout from their collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world. The data, published today in Cancer Research Communications, a journal of the American Association for Cancer Research, found that Guardant Reveal succe.
Neutral
Business Wire
2 weeks ago
First Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection Test
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)'s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant's Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—.
Neutral
Business Wire
2 weeks ago
Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will.
Positive
Zacks Investment Research
1 month ago
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.
Neutral
Investors Business Daily
1 month ago
Medical Services Name Flirts With A Buy Point
This medical services stock is in a cup-with-handle base. The biotech's tests detect cancer through blood tests.
Neutral
Business Wire
1 month ago
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company's 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world's most urgent challenges. Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC.
Neutral
Business Wire
1 month ago
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company's minimal residual disease (MRD) blood test, in predicting recurrence in patients with early-stage breast cancer. Guardant Reveal uses epigenomic (methylation) analysis to detect circula.
Positive
The Motley Fool
1 month ago
Why Guardant Health Stock Surged Nearly 9% Higher Today
Precision oncology specialist Guardant Health (GH 8.53%) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped almost 9% higher today.
Positive
Benzinga
1 month ago
Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?
Guardant Health, Inc. GH stock is trading higher on Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the company's Shield multi-cancer detection (MCD) test.
Neutral
Business Wire
1 month ago
FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 4.
Charts implemented using Lightweight Charts™